DBV Technologies Back in Focus as Investors Reassess Peanut-Allergy Market After Nestlé’s $2.6bn Aimmune Bet
Paris, Dec. 8 — DBV Technologies is drawing renewed attention in the food-allergy treatment space as the company advances its epicutaneous immunotherapy patch, Viaskin Peanut, while the sector’s largest historical investor, Nestlé, has fully exited its previous peanut-allergy exposure.
DBV trades at a market capitalization of ~$520 million, with investor sentiment supported by the company’s March 2025 financing package of up to $306.9 million aimed at completing regulatory pathways and preparing for potential U.S. market entry. The FDA has agreed on a regulatory framework enabling DBV to proceed toward a BLA filing for children aged 4–7, expected in 2026.
The competitive backdrop remains defined by Nestlé’s earlier move into the category: in 2020, the Swiss group acquired Aimmune Therapeutics — developer of the oral peanut-allergy therapy Palforzia — for $2.6 billion in cash. Palforzia became the first FDA-approved treatment to reduce severity of allergic reactions to accidental peanut exposure. However, adoption lagged, and Nestlé divested the asset to Stallergenes Greer in September 2023, citing weak commercial traction.
The divergence underscores shifting expectations in the sector: DBV is positioning a less invasive patch-based approach that may offer improved tolerability versus oral desensitization, while the previous market leader has stepped away after a costly and underperforming entry.
Investors now watch whether DBV — whose valuation remains far below the price Nestlé once paid for Aimmune — can translate regulatory progress into a viable commercial pathway in a market still seeking scalable, physician-friendly solutions.